HIV Clinical Trials Must Enroll More Women
March 6, 2017
In an interview on behalf of IFARA at CROI 2017, Andy Kaytes spoke with Rena Patel, M.D., and Monica Gandhi, M.D., about HIV in women. Studies have shown that women taking certain forms of hormonal contraceptives have a higher risk of acquiring HIV than those who do not use such pregnancy prevention.
Pregnancy presents a unique opportunity to identify and reach women who may benefit from oral pre-exposure prophylaxis. Studies have not shown adverse birth outcomes for women who took tenofovir disproxil fumarate (TDF, Viread)) during pregnancy.
A newer form of this drug, tenofovir alafenamide (TAF, Vemlidy), may accumulate at lower levels in vaginal tissue than in rectal tissue. Yet, the current clinical trial comparing TDF and TAF has not enrolled any cisgender women. To understand the biological and social differences that contribute to divergent responses to HIV prevention and treatment in women and men, enrolling women in clinical investigations must become a priority.
Watch the video to learn more:
The video above has been posted on TheBodyPRO.com with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the conference, as well as earlier meetings.
Follow Barbara on Twitter: @reliabletran.
This article was provided by TheBodyPRO. It is a part of the publication The 24th Conference on Retroviruses and Opportunistic Infections.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.